Evidence map›Paper›PMID 35878263›Full record

ArticleToxics2022

Emerging Contaminant Imidacloprid in Mediterranean Soils: The Risk of Accumulation Is Greater than the Risk of Leaching.

Mirna Petković Didović, Tomasz Kowalkowski, Dalibor Broznić

Abstract read
In one paragraph

Article in Toxics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mirna Petković DidovićDepartment of Medical Chemistry, Biochemistry and Clinical Chemistry, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia.ORCID 0000-0002-6028-5429
Tomasz KowalkowskiEnvironmental Chemistry and Bioanalytics, Faculty of Chemistry, Nicolaus Copernicus University, Gagarina 7, 87-100 Toruń, Poland.ORCID 0000-0001-8866-0246
Dalibor BroznićDepartment of Medical Chemistry, Biochemistry and Clinical Chemistry, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia.ORCID 0000-0003-3935-5338

Funding

University of Rijeka uniri-biomed-18-155-1304
6 · The paper itself

Abstract

Imidacloprid (IMI) is an extensively used neonicotinoid insecticide whose occurrence in the environment is a worldwide problem. Its sorption/transport properties are recognized as one of the key knowledge gaps hindering policymaking regarding its international routine monitoring in soils. Therefore, we studied IMI transport behaviour in Croatian Mediterranean soils using column experiments. Breakthrough curves were analysed using the two-site adsorption model and compared against dimethoate (DIM). Transport parameters were correlated to soil physicochemical properties. The results indicate that IMI shows a high degree of preference for soil organic matter over any other soil constituent. For IMI, the clay did not exhibit any sorption activity, while hematite did act as an active sorbent. Contrarily, hematite increased the leachability of DIM by blocking the active sorption sites on clay platelets. Both hematite and clay sorption acted as type-2 (i.e., rate-limiting) sites. In all soils, IMI exhibited lower short-term leachability than DIM. Combined with a body of data concerning other aspects of IMI environmental behaviour, the results indicate that the risk of accumulation of IMI in the soil is greater than the risk of contamination by leaching. Thus, continuous monitoring of IMI in soils should be incorporated into future soil health protection programs.

Indexed as

emerging pollutanthematiteleachingneonicotinoidssoil healthsorption

Identifiers

PMID35878263
PMCPMC9323270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.